Biop Medical Uses IBM's Cloud to Detect Cervical Cancer

Cervical cancer is now the second most common cause of cancer death in women worldwide. More than ten thousand new cases of cervical cancer are diagnosed each year in the US, and more than 400 in Israel. According to the Centers for Disease Control (CDC), 3,800 women in the US die each year from this disease. Early detection of the disease is critical to increase the survival chances of the sick women. Scanning processes, diagnosis, monitoring and early detection of cervical cancer impose a heavy burden on health care systems - and a real burden on women under surveillance.

Israeli firm, Biop Medical, offers a new approach to these tasks. The optical scanner portable probe , developed by Biop, uses several optical phenomena, and is designed in a unique optical and mechanical structure, suited to the work of the doctor. According to Ilan Landsman, CEO and co-founder of Biop, "The system can translate the optical seal relative to the state of tissue of the cervix: it identifies the correlation between the optical signature and the biological tissue condition, and sends this information to IBM's cloud environment. There, runs an algorithm that performs the analysis process of various phenomena, and deciphering is received within a few minutes". Through the ongoing work, the system aggregates data and builds a growing database of raw data in the cloud. Unique tools from IBM perform analysis of the scanned images, and also predict future risks and recommend additional tests.

Ilan Landsman, CEO and co-founder of Biop and Oz Seadia, Project Manager

Landesman expects that Biop's  system, small and easy to purchase and operate, will make it possible for governments and health bodies, to offer tailored and personally customized prevention programs for women and continuous surveillance to identify cervical cancer.
In the next phase, he believes, the system will pave the way for remote medicine and tele medicine, when images stored in the database are sent for analysis at a remote site. Thus, it is also possible to compare each test to millions of other tests - and offer improved accuracy in the diagnostic process.

Biop was founded in 2013, operated as part of the Israeli Chief Scientist's incubator, and was selected to participate in the first cycle of IBM's  AlphaZone acceleration program. This program supports the development of innovative applications in the cloud and offers an easy access to IBM's experts and researchers, as well as connections to IBM's ecosystem, business partners and customers. Biop has completed the development of a prototype of the scanning device, and is currently conducting clinical experiments in Israel and in Europe. Recently, Biop was selected as a finalist in a prestigious international competition for startup companies in the medical field, conducted by the Cleveland Clinic Hospital in the US.

Dror Pearl, the IBM Global Technology Unit (GTU) Leader, sees Biopas an excellent example to the way developers used IBM's platform as a service in the cloud, called Bluemix. Bluemix allows rapid and secure coding and testing process while meeting enterprise standards. It  simplifies the process of transition to future development and operational phases. "Working in Bluemix releases the developer from the need to deal with infrastructure management and hosting dependencies. They can focus only on the real wisdom that matters - the core of the new application", says Pearl.